HMPL-453

HMPL-453 is a small-molecule drug developed by Hutchmed. Its target is FGFR2 (the sponsor names FGFR2). ClinicalTrials.gov describes the intervention as: Cohort\_1:HMPL-453 150mg QD continuously in 21-day cycles; Cohort\_2, Cohort\_3 and Cohort\_4:HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days \[Day 1 to 14\], followed by 7 days off \[Day 15 to 21\], 21 days as a treatment cycle. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT04353375 (HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma), in biliary tract cancer. The largest, NCT04353375, plans to enrol 235 participants with primary completion expected 2028-06-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.